Background: The aim of this study was to evaluate the efficacy of the combination of epirubicin, cisplatin and ralitrexed (Tomudex), ECT, in patients with advanced oesophageal or gastric adenocarcinoma. Efficacy was assessed primarily as response rate and secondarily in terms of toxicity, time to progression and survival.
Introduction
Combination chemotherapy results in a significant survival advantage in patients with advanced gastric cancer compared with best supportive care [1, 2] . High response rates (60%-70%), may be obtained with protracted infusional 5-fluorouracil (5-FU), cisplatin and epirubicinthe ECF regimen [3, 4] . ECF results in significantly better response rates (45%) and median survival (8.9 months), with significantly less toxicity when compared to the FAMtx regimen [5] and is now considered the treatment regimen of choice in inoperable adenocarcinoma of the oesophagus and stomach in the UK.
However, the ECF regimen requires the protracted venous infusion of 5-FU via a Hickman catheter, which is associated with significant morbidity particularly venous thrombosis [5] . As inhibition of thymidylate synthase (TS) is an important mechanism of action of infusional 5-FU, one potential strategy to replace this would be to use a specific TS inhibitor in combination with epirubicin and cisplatin.
Raltitrexed (Tomudex) is a quinazolone-based water soluble anti-folate which is extensively and efficiently polyglutamated and has demonstrable single agent activity [6] [7] [8] . Furthermore, several studies have demonstrated that raltitrexed is tolerable and active in combination with other cytotoxic agents including 5-FU and the anthracyclines [9, 10] .
We have previously determined the optimal dose of raltitrexed (2.5 mg/m") in combination with epirubicin (50 mg/m 2 ) and cisplatin (60 mg/m 2 ) in patients with advanced gastro-oesophageal adenocarcinoma [11] . The phase I study reported an overall response rate of 33% (7 PR and 1 CR) with a median survival of 9.9 months and with neutropaenia and diarrhoea as the dose limiting Statistical analysis toxicities [11] .
The aim of this phase II study was to determine if this regimen gives an objective response rate warranting comparison with ECF within a phase III randomised trial.
Survival and time to progression were measured from the date the patient was enrolled into the study. For the progression end-point deaths from causes other than disease were treated as censoring events.
Patients and methods Results

Patient selection
This was a non-randomised phase II study, performed at the Beatson Oncology Centre, Glasgow. Glasgow Royal Infirmary. Churchill Hospital, Oxford and St George's Hospital. London. The study was approved by the Local Research Ethics Committee at each of the participating institutions. All patients entered into this study had histologically or cytologically confirmed inoperable adenocarcinoma of the oesophagus, stomach or gastro-oesophageal junction with at least one site of bi-dimensionally measurable disease and to have received no prior chemotherapy for advanced disease. All other eligibility criteria were as previously reported [II] , except for renal function (creatinine clearance: gfr = 65 ml/min). Written informed consent was obtained for all patients prior to starting treatment Treatment Epirubicin (50 mg/nr), cisplatin (60 mg/m 2 ) and ralitrexed (2.5 mg/m 2 ) were administered on day 1 and then every 21 days for up to a maximum of 6 cycles of treatment. Raltitrexed was administered as a short intravenous infusion over 15 minutes prior to cisplatin on day 1 of a three-weekly cycle. Cisplatin was administered as an intravenous infusion over four hours with standard pre and post hydration schedules, electrolyte supplementation and anti-emetics.
Evaluation oj toxiciiv and tumour response
Pre-treatment investigations included clinical examination, full blood count, biochemical profile. ECG and chest X-ray. CT scan of the abdomen and other sites of disease, as appropriate, was performed for disease assessment up to three weeks prior to starting chemotherapy. Patients had full blood count, biochemical profile and calculation of GFR and clinical assessment every three weeks. Toxicity was graded according to NCIC-CTC expanded common toxicity criteria. Disease measurements were performed after three and six cycles of chemotherapy by the same techniques as at pre-treatment evaluation. Patients with stable disease or who were responding received a maximum of six cycles of chemotherapy, with a final disease assessment performed within four weeks of completing the final course of chemotherapy. Response was determined according to the modified SWOG response criteria for solid tumours. Subsequent CT scans and endoscopy were not performed routinely but at the investigators discretion. The time to disease progression was defined as the time from the start of chemotherapy until subsequent disease progression. Overall survival was determined from the start of chemotherapy to the time of death (all causes).
Dose delays and modifications
Dose delays and modifications were performed on the basis of toxicity and was as previously described [II] except for modification of Tomudex based on renal function. GFR was measured according to the Cockcroft-Gault formula prior to each cycle of treatment. If the GFR was <65 ml/min by this method EDTA was performed. The dose of Tomudex was modified in line with the creatinine clearance >65 ml/min full dose every 21 days, 25-64 ml/min = 50% of starting dose at a 28-day interval. < 25 ml/min = no further treatment.
Twenty-one patients (15 men and 6 women) were enrolled in this phase II study. They received a total of 68 cycles of chemotherapy with a median of 3 cycles per patient (range 0-6). The median age was 62 (range 37-74). None of the patients had received prior chemotherapy. Additional patient characteristics are shown in Table 1 .
Response and survival
The overall response rate (CR plus PR) was 29% (95% CI: ll%-52%). Four patients (19%) had disease stabilisation. A total of 12 patients have developed progressive disease. The median time to progression was 19 weeks (95% CI: 7-31 weeks). The median survival time was 18 weeks (95% CI: 11-24 weeks). The median follow up for the 7 patients who remain alive is 19 weeks (range 9-37 weeks). A total of 14 patients have died since the study started, due to progressive disease (8), treatment related toxicity (3), myocardial infarction (1), infection (1) and pulmonary embolism (1).
Toxicity
Twenty patients (68 cycles of chemotherapy) were evaluable for toxicity. Grade 3-4 non-haematological toxicities were nausea and vomiting (2 patients), diarrhoea (3), constipation (1) and fatigue (4). Six patients experienced grade 3-4 neutropaenia complicated by sepsis. Seven patients required packed cell transfusion on a total of eight occasions. One patient experienced grade 3-4 thrombocytopaenia. All toxicities are further summarised in Table 2 .
Biochemical toxicity was minimal with no patients developing grade 2 or worse derangement in liver function tests.
Seventeen patients failed to complete six cycles of ECT due to: progressive disease (5) toxic death (3), nontoxic death (3), allergic reaction to epirubicin (1), patient request (1) and trial suspension (5). The toxic deaths occurred as a result of cardiorespiratory complications following chemotherapy induced enteritis in one patient and grade 3-4 neutropaenic sepsis in the remaining two patients. One further patient died from treatment related toxicity toxicity following six cycles of treatment.
There was a total of seven delayed cycles due to neutropaenia (3), grade 3 nausea (1), angina (1) and in two cases the cause is unknown.
The dose of Tomudex was reduced in four patients due to grade 2 diarrhoea (2), renal impairment (1) and grade 4 neutropaenia with infection (1). In accordance with the protocol, the cisplatin was modified in one patient with reduced creatinine clearance and the dose of epirubicin reduced due to neutropaenic sepsis in a second patient. One patient discontinued treatment following a severe allergic reaction to epirubicin without receiving any cisplatin orTomudex. In view of the toxicities associated with this regimen, this phase II study was discontinued early. The experience of toxicities within this study was different from that observed within the phase I study of this combination [11] . The original aim of this phase II study was to determine the response rate, with sufficient confidence, in patients with oesophagogastric cancer. Consequently in order to determine the likely response rate with this regimen we have combined the response rates in patients within the phase I and phase II studies, thereby enabling us to decide whether the response rates would justify (55) 1 (5) 0 attempting to pursue this regimen further with modifications to reduce toxicity. The combined response rate was 31%, 14 of 45 (95% CI: 18%-47%).
Discussion
The ECF regimen gives high response rates but overall survival remains disappointing and the presence of Hickman lines is associated with significant morbidity [5] . Consequently the development of novel chemotherapy agents which can be incorporated into combination chemotherapy regimens remains an important challenge for further improving the outcome of patients with oesophagogastric carcinoma.
We have previously shown that the use of Tomudex in combination with epirubicin and cisplatin is tolerable and has promising activity within the context of a phase I trial [11] . The response rate in this study was 29% (95% confidence limits: ll%-52%), as compared to 38% (95% CI: 21%-55%) in the phase I study [11] . These rates do not compare favourably with those reported for ECF in phase III randomised trials [5] . Furthermore, the median overall survival in this study was 4.1 months compared to 6 months in the ECT phase I study and 8.9 months for ECF. Consequently even if toxicity was manageable with this regimen, the level of activity of this regimen suggests that it is likely to be inferior to ECF.
The reasons for the unexpected toxicity seen in this study are not entirely clear. Tumour involvement of the upper gastrointestinal tract causes nausea, anorexia, fatigue and compromised nutritional status, increasing the potential toxicities associated with chemotherapy. Patients treated in the phase I study were of generally better performance status (ECOG 0%-42%) than in this study (ECOG 0%-14%). In addition a higher percentage (87%) of patients had tumours of the oesophagus and OG junction compared to the phase I study (42%) [11] and the randomised trial of ECF versus FAMTx (42%) [5] . It may well be that the patients included in this study were less fit, and experiencing more tumour-related morbidity prior to commencing treatment. It has been suggested that the toxicity observed with single agent tomudex is associated with compromised renal function [12] . All patients had a creatinine clearance of > 65 ml/ min*at study entry and this was re-calculated prior to each cycle of treatment and only 1 patient required does modification for reduced creatinine clearance who did not experience additional toxicity.
The combination of epirubicin, cisplatin and Tomudex is active in oesophagogastric adenocarcinoma. Combining the activity in the phase I and II studies gives a response rate of 31% (CI: 18%-47%), which is less than that observed with ECF in phase III trials. This, together with the degree of toxicity, suggests that it would not be appropriate to proceed to a randomised phase III study in comparison with ECF, even if the toxicity could be reduced.
